NCT06414135View on ClinicalTrials.gov

Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

April 30, 2027

Conditions
Systemic Sclerosis
Interventions
BIOLOGICAL

Relma-cel

All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells

Trial Locations (1)

200001

RECRUITING

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY

lead

Liangjing Lu

OTHER

NCT06414135 - Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis | Biotech Hunter | Biotech Hunter